485 related articles for article (PubMed ID: 31735345)
21. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management.
Malpica L; Marques-Piubelli ML; Beltran BE; Chavez JC; Miranda RN; Castillo JJ
Am J Hematol; 2022 Jul; 97(7):951-965. PubMed ID: 35472248
[TBL] [Abstract][Full Text] [Related]
22. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, in the Oral Cavity.
Costa SFDS; Silva AMB; Amaral-Silva GK; Pontes HAR; Pontes FSC; Fonseca FP; Almeida OP
J Craniofac Surg; 2019; 30(3):e259-e262. PubMed ID: 31048622
[TBL] [Abstract][Full Text] [Related]
24. Primary cutaneous, composite, Epstein-Barr virus-associated, diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
Papalas JA; Puri PK; Sebastian S; Wang E
Am J Dermatopathol; 2011 Oct; 33(7):719-25. PubMed ID: 21946762
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
[TBL] [Abstract][Full Text] [Related]
26. Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment.
Paulli M; Lucioni M; Maffi A; Croci GA; Nicola M; Berti E
G Ital Dermatol Venereol; 2012 Dec; 147(6):589-602. PubMed ID: 23149705
[TBL] [Abstract][Full Text] [Related]
27. Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells.
Ohashi A; Kato S; Okamoto A; Inaguma Y; Satou A; Tsuzuki T; Emi N; Okamoto M; Nakamura S
Histopathology; 2017 Jul; 71(1):89-97. PubMed ID: 28231401
[TBL] [Abstract][Full Text] [Related]
28. [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].
Lamos C; Dippel E
Hautarzt; 2017 Sep; 68(9):727-739. PubMed ID: 28815289
[TBL] [Abstract][Full Text] [Related]
29. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
[TBL] [Abstract][Full Text] [Related]
30. An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified.
Hoffmann JC; Chisholm KM; Cherry A; Chen J; Arber DA; Natkunam Y; Warnke RA; Ohgami RS
Hum Pathol; 2016 Feb; 48():9-17. PubMed ID: 26772393
[TBL] [Abstract][Full Text] [Related]
31. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far.
Castillo JJ; Beltran BE; Miranda RN; Paydas S; Winer ES; Butera JN
Oncologist; 2011; 16(1):87-96. PubMed ID: 21212426
[TBL] [Abstract][Full Text] [Related]
32. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
[TBL] [Abstract][Full Text] [Related]
33. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.
Beltran BE; Castro D; Paredes S; Miranda RN; Castillo JJ
Am J Hematol; 2020 Apr; 95(4):435-445. PubMed ID: 32072672
[TBL] [Abstract][Full Text] [Related]
34. Development of EBV-encoded small RNA targeted PCR to classify EBV positive diffuse large B-cell lymphoma (DLBCL) of the elderly.
Lee J; Park M; Lee MH; Woo HJ; Kim HW; Yang JY; Eom YB; Kim SH; Yoo C; Kim JB
Int J Clin Exp Pathol; 2015; 8(7):7859-68. PubMed ID: 26339350
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].
Xu FP; Liu YH; Zhuang HG; Luo DL; Li L; Zhang F; Luo XL; Du X; Li WY; Chen Q
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):616-21. PubMed ID: 22177246
[TBL] [Abstract][Full Text] [Related]
36. HHV8-positive, EBV-positive Hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma.
Ferry JA; Sohani AR; Longtine JA; Schwartz RA; Harris NL
Mod Pathol; 2009 May; 22(5):618-26. PubMed ID: 19287457
[TBL] [Abstract][Full Text] [Related]
37. pSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Teoh SH; Khoo JJ; Abdul Salam DSD; Peh SC; Cheah SC
Malays J Pathol; 2019 Dec; 41(3):273-281. PubMed ID: 31901912
[TBL] [Abstract][Full Text] [Related]
38. The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma.
Healy JA; Dave SS
Curr Top Microbiol Immunol; 2015; 390(Pt 1):315-37. PubMed ID: 26424652
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland.
Ziarkiewicz M; Wołosz D; Dzieciątkowski T; Wilczek E; Dwilewicz-Trojaczek J; Jędrzejczak WW; Gierej B; Ziarkiewicz-Wróblewska B
Arch Immunol Ther Exp (Warsz); 2016 Apr; 64(2):159-69. PubMed ID: 26084760
[TBL] [Abstract][Full Text] [Related]
40. Epstein Barr Virus Infection Can be a Secondary Event in B-Cell Lymphomas: A Review of 338 Cases and a Novel Finding of Zonal EBER+ Tumor Cells Showing Features of Progression From Underlying EBV-negative Lymphoma.
Miller IJ
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):165-173. PubMed ID: 28800008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
